Here are nine key notes:
1. Invibio settled with the FTC to resolve allegations that the company used exclusive supply agreements to maintain its monopoly in the high-tech polymer material market.
2. Invibio was the sole supplier of the implant-grade PEEK polymer until the late 2000s, when Solvay Specialty Polymers and Evonik entered the market.
3. Solvay and Evonik began selling PEEK polymer at prices lower than Invibio.
4. Invibio allegedly tried to broaden the exclusivity provisions in its customer agreements.
5. According to the FTC complaint, the company allegedly threatened to withhold PEEK supply to existing products for customers if they did not accept the provisions. These tactics allowed Invibio to maintain a 90 percent market share with high prices for PEEK.
6. The FTC has proposed a consent order that would prohibit Invibio, and its parent company Vitrex, from entering into contracts with certain exclusive clauses in the future.
7. The consent order also allows consumers to modify existing contracts. Additionally, it requires Invibio to set up an antitrust compliance program for employees.
More articles on devices:
5 statistics on global hip & knee replacement market share
Stryker, Smith & Nephew, K2M & more: 18 key notes
Integra Cadence Total Ankle successfully used in first 10 procedures: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
